Literature DB >> 94196

Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications.

Y Copelovici, D Strulovici, A L Cristea, V Tudor, V Armaşu.   

Abstract

Administration of specific antimumps immunoglobulins(Ig) to mumps contacts in various children communities conferred protection only when performed early after the outbreak of the epidemic and if the proportion of previous mumps cases did not surpass 8% of the total number of children. Application of specific Ig to mumps patients within the first 5 days after onset prevented the appearance of secondary determinations and/or complications and reduced the duration of the disease and of the hospitalization period. The efficiency of standard gamma-globulins was very limited.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94196

Source DB:  PubMed          Journal:  Virologie        ISSN: 0253-181X            Impact factor:   0.474


  4 in total

1.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

2.  Immunogenicity of mumps virus vaccine candidates matching circulating genotypes in the United States and China.

Authors:  James Zengel; Shannon I Phan; Adrian Pickar; Pei Xu; Biao He
Journal:  Vaccine       Date:  2017-06-13       Impact factor: 3.641

3.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.